Stanford Medicine’s “Scope” blog discusses results of a study recently published in The Lancet on the efficacy of a rotavirus vaccine in India. The vaccine was spearheaded by an Indian biotechnology company, Bharat Biotech, and “has leaped the safety and efficacy thresholds of a late-stage clinical trial, in which more than 6,500 Indian infants were inoculated, and will likely become available in that country for less than a dollar a dose. … [T]he effort to capitalize on this promising episode of serendipity drew financial support from the Bill & Melinda Gates Foundation and technical assistance from the Government of India’s Department of Biotechnology, the United States’ Centers for Disease Control and Prevention, and Stanford, among others. This international team of collaborators then spent more than 15 years turning the promise into a reality” (Goldman, 3/17).